Jeffrey S. Hatfield Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jeffrey S. Hatfield.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jeffrey S. Hatfield. Jeffrey S. Hatfield is Director in AMBIT BIOSCIENCES CORP ($AMBI) and Chief Executive Officer in Vitae Pharmaceuticals, Inc ($VTAE) and Director in INVIVO THERAPEUTICS HOLDINGS CORP. ($NVIV) and Director in aTYR PHARMA INC ($LIFE) and Chief Executive Officer in ZAFGEN, INC. ($ZFGN) and Director in MIRAGEN THERAPEUTICS, INC. ($MGEN) and Director in Vir Biotechnology, Inc. ($VIR).
Latest Insider Trading Transactions of Jeffrey S. Hatfield
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AMBI, LIFE, NVIV, LRMR, VIR, MGEN, VTAE
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 08 2021 | MGEN | Viridian Therapeut ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 20.50 | 25,000 | 512,500 | 25,000 | |
| Dec 11 2020 | VIR | Vir Biotechnology, ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 29.43 | 46,500 | 1,368,495 | 46,500 | |
| May 22 2020 | MGEN | MIRAGEN THERAPEUTI ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 0.63 | 24,000 | 15,026 | 24,000 | |
| May 08 2020 | LIFE | aTYR PHARMA INC | Hatfield Jeffrey S. | Director | Option Exercise | A | 3.65 | 1,428 | 5,212 | 1,428 | |
| Jun 21 2019 | MGEN | MIRAGEN THERAPEUTI ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 2.36 | 12,000 | 28,320 | 12,000 | |
| May 10 2019 | LIFE | aTYR PHARMA INC | Hatfield Jeffrey S. | Director | Option Exercise | A | 0.58 | 20,000 | 11,668 | 20,000 | |
| Jan 24 2019 | ZFGN | ZAFGEN, INC. | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 4.63 | 525,000 | 2,430,750 | 525,000 | |
| Jun 28 2018 | MGEN | MIRAGEN THERAPEUTI ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 6.46 | 12,000 | 77,520 | 12,000 | |
| Jun 28 2018 | MGEN | MIRAGEN THERAPEUTI ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 6.46 | 12,000 | 77,520 | 12,000 | |
| May 17 2018 | LIFE | aTYR PHARMA INC | Hatfield Jeffrey S. | Director | Option Exercise | A | 1.35 | 20,000 | 27,000 | 20,000 | |
| Feb 23 2018 | ZFGN | ZAFGEN, INC. | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 7.77 | 275,000 | 2,136,750 | 275,000 | |
| Jan 23 2018 | NVIV | INVIVO THERAPEUTIC ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 0.69 | 12,500 | 8,625 | 12,500 | |
| Dec 29 2017 | ZFGN | ZAFGEN, INC. | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 3.40 | 1,100,000 | 3,740,000 | 1,100,000 | |
| Oct 11 2017 | ZFGN | ZAFGEN, INC. | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 3.40 | 550,000 | 1,870,000 | 550,000 | |
| May 11 2017 | LIFE | aTYR PHARMA INC | Hatfield Jeffrey S. | Director | Option Exercise | A | 3.15 | 20,000 | 63,000 | 20,000 | |
| Nov 03 2016 | NVIV | INVIVO THERAPEUTIC ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 4.25 | 25,000 | 106,250 | 25,000 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 8.78 | 60,000 | 526,800 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 8.58 | 60,000 | 514,800 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 8.28 | 50,000 | 414,000 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 14.40 | 50,000 | 720,000 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 7.13 | 134,782 | 960,996 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 6.90 | 10,320 | 71,208 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.91 | 20,869 | 81,598 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.91 | 6,245 | 24,418 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.45 | 30,434 | 104,997 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | D | 3.45 | 26,086 | 89,997 | 0 | |
| Oct 25 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Sell | U | 21.00 | 244,996 | 5,144,916 | 244,996 | 490 K to 245 K (-50.00 %) |
| Sep 16 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Sell | S | 20.81 | 50,000 | 1,040,500 | 244,996 | 295 K to 245 K (-16.95 %) |
| Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 8.79 | 60,000 | 527,400 | 60,000 | |
| Aug 17 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Grant | A | 6.11 | 747 | 4,564 | 294,996 | 294.2 K to 295 K (+0.25 %) |
| Feb 16 2016 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 8.58 | 60,000 | 514,800 | 60,000 | |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 3.45 | 26,537 | 91,553 | 0 | |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 3.45 | 16,940 | 58,443 | 0 | |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 3.45 | 5,584 | 19,265 | 0 | |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 3.45 | 26,537 | 91,553 | 293,897 | 267.4 K to 293.9 K (+9.93 %) |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Sell | S | 17.00 | 22,524 | 382,908 | 267,360 | 289.9 K to 267.4 K (-7.77 %) |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 3.45 | 16,940 | 58,443 | 289,884 | 272.9 K to 289.9 K (+6.21 %) |
| Dec 28 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 3.45 | 5,584 | 19,265 | 272,944 | 267.4 K to 272.9 K (+2.09 %) |
| Mar 17 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Payment of Exercise | F | 11.16 | 171,156 | 1,910,101 | 267,360 | 438.5 K to 267.4 K (-39.03 %) |
| Mar 09 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | M | 1.15 | 8,115 | 9,332 | 0 | |
| Mar 09 2015 | VTAE | Vitae Pharmaceutic ... | Hatfield Jeffrey S. | Chief Executive Off ... | Buy | M | 1.15 | 8,115 | 9,332 | 438,516 | 430.4 K to 438.5 K (+1.89 %) |
| Nov 12 2014 | AMBI | AMBIT BIOSCIENCES ... | Hatfield Jeffrey S. | Director | Option Exercise | D | 6.69 | 14,000 | 93,660 | 0 |
Page: 1